Clinical Trial Update: 99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating 99mTc-ADAPT6 SPECT imaging to quantify HER2-expression non-invasively in breast cancer with metastatic lymph nodes; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 99mTc-ADAPT6

Snippet

Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences | Conditions: Breast Cancer, Female | Phase 2 | Status: COMPLETED